Adlai Nortye (NASDAQ:ANL) and Pharming Group (NASDAQ:PHAR) Head to Head Survey

Pharming Group (NASDAQ:PHAR) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Insider and Institutional Ownership

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Pharming Group and Adlai Nortye’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pharming Group	0.30%	0.46%	0.25%
Adlai Nortye	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Pharming Group and Adlai Nortye, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	0	2	2	0	2.50
Adlai Nortye	1	1	0	0	1.50

Pharming Group presently has a consensus target price of $38.00, indicating a potential upside of 121.19%. Given Pharming Group’s stronger consensus rating and higher possible upside, analysts plainly believe Pharming Group is more favorable than Adlai Nortye.

Earnings & Valuation

This table compares Pharming Group and Adlai Nortye”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$297.20 million	3.96	-$11.84 million	($0.01)	-1,718.00
Adlai Nortye	$5.00 million	10.55	-$51.87 million	N/A	N/A

Pharming Group has higher revenue and earnings than Adlai Nortye.

Summary

Pharming Group beats Adlai Nortye on 9 of the 11 factors compared between the two stocks.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.